<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129309">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01742676</url>
  </required_header>
  <id_info>
    <org_study_id>ADV-KT-03</org_study_id>
    <nct_id>NCT01742676</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Safety and Efficacy of Once-daily ADVAGRAF With Twice-daily PROGRAF in Stable Renal Recipients</brief_title>
  <acronym>SINGLE</acronym>
  <official_title>A Single Center, Open-label, Randomized Pilot Study to Evaluate the Safety and Efficacy of Modified-release Tacrolimus, ADVAGRAF速, Versus Those of Twice-daily Tacrolimus, PROGRAF速, in Stable Renal Recipients (SINGLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Korea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate and compare the safety and efficacy of two drugs
      (ADVAGRAF速 and PROGRAF速 groups) in patients who received renal transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>at 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate (GFR)</measure>
    <time_frame>at 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Calculated by Modification of Diet in Renal Disease equation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of rejection reactions</measure>
    <time_frame>at 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>at 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate of the grafts</measure>
    <time_frame>at 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's physical condition (SF-35)</measure>
    <time_frame>at 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of subject's physical condition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Renal Transplantation</condition>
  <condition>Kidney Transplantation</condition>
  <condition>Stable Renal Recipients</condition>
  <arm_group>
    <arm_group_label>ADVAGRAF group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PROGRAF group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADVAGRAF</intervention_name>
    <description>oral</description>
    <arm_group_label>ADVAGRAF group</arm_group_label>
    <other_name>modified release tacrolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PROGRAF</intervention_name>
    <description>oral</description>
    <arm_group_label>PROGRAF group</arm_group_label>
    <other_name>twice-daily tacrolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Only patients who meet the following inclusion criteria should be enrolled.

          1. Patients who received a kidney at least within 12 months of their study enrollment
             (from a deceased or living donor)

          2. Patients whose tacrolimus dose have not been changed in at least 12 weeks from their
             study enrollment and whose minimum blood tacrolimus concentration mean value is
             within 3-10 ng/ml

          3. Female patients who showed a negative result in the serum pregnancy test and who
             agreed to use an effective contraceptive method during the study period

          4. Patients who are clinically stable based on the judgment of the investigator

          5. Patients who were given enough information regarding the study, understood the
             objectives and risks of the study, and signed the informed consent form

        Exclusion Criteria:

        Patients who fall under any of the following criteria should not be enrolled in this
        study.

          1. Patients who had received any other organ except a kidney

          2. Patients who showed an acute rejection reaction within 12 weeks of their enrollment
             or who showed an acute rejection reaction that required antilymphocyte antibody
             therapy within 24 weeks

          3. Patients who were diagnosed with a newly developed malignant tumor (Patients with
             successfully treated squamous cell/basal cell carcinoma can be enrolled, though.)

          4. Patients who have a known allergy to the investigational drug (the test/control drug)
             or to tacrolimus

          5. Patients who have an unstable medical condition that may affect the evaluation of the
             study's objectives based on the investigator's judgment

          6. Patients who have any form of drug abuse or mental illness that might complicate
             communication with the investigators based on the investigator's judgment

          7. Patients who are currently participating in another clinical trial or who received
             the investigational drug in another trial within 28 days of their enrollment

          8. Patients who are receiving prohibited concomitant medications or who received those
             medications within 28 days of their enrollment

          9. Patients who are pregnant or breastfeeding

         10. Patients who had been HIV-positive

         11. Patients who are considered non-compliant with the scheduled study visits in the
             protocol

         12. Patients who have abnormal kidney functions or a serum creatinine level higher than
             1.6 mg/dL/GFR (MDRD) or less than 30 mL/min at the screening visit

         13. Patients who have &quot;Creeping creatinine&quot; (a 20% increase in their creatinine for six
             months before their enrollment)

         14. Patients who have abnormal liver functions: i.e., whose SGPT/ALT and/or SGOT/AST
             and/or bilirubin is twice higher than the normal range in the center, and who have
             liver cirrhosis

         15. Patients who have an underlying disease such as focal segmental glomerulosclerosis
             (FSGS) or type II membranoproliferative glomerulonephritis (Type II MPGN)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 8, 2013</lastchanged_date>
  <firstreceived_date>December 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tacrolimus</keyword>
  <keyword>kidney</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
